## Claims

- A process for synthesizing biopolymers by stepwise 1. from synthesis building blocks which assembly least carry protective groups, where at 5 synthesis building block which carries a two-stage protective group is used, where the two-stage protective group is activated by an illumination eliminated by a subsequent chemical step and characterized in that the treatment step, 10 elimination of а activation takes place by group photoactivatable protective selected from triplet-sensitized photoactivatable photoactivatable labeled groups and groups, triplet-sensitized and labeled photoactivatable 15 groups.
- The process as claimed in claim 1, characterized in that the chemical treatment step comprises a treatment with base, a treatment with acid, an oxidation, a reduction or/and a catalyzed, e.g. enzymatic, reaction.
- 3. The process as claimed in claim 2, characterized in that the chemical treatment step comprises an acid treatment.
- The process as claimed in any of claims 1 to 3, characterized in that a derivatized trityl group
   is used as two-stage protective group.

35

5. The process as claimed in claim 4, characterized in that the synthesis building block with the two-stage protective group has the general formula (I):

$$R_2$$
 $M_m$ 
 $M_m$ 
 $M_m$ 
 $M_m$ 

where  $R_1$  and  $R_2$  are each independently selected from hydrogen, (L)- $R_3$ , -O-(L)- $R_3$ , N( $R_3$ )<sub>2</sub>, NHZ and M,


 $R_3$  is a  $C_1$ - $C_8$  alkyl group, a  $C_2$ - $C_8$ -alkenyl group, a  $C_2$ - $C_8$ -alkynyl group, a  $C_6$ - $C_{25}$ -aryl group or/and a  $C_5$ - $C_{25}$ -heteroaryl group, which may optionally have substituents,

L is a linker group which is optionally present, X is the synthesis building block,

5

M is in each case independently a label optionally linked via a linker group, and m is in each case independently an integer from 0 to 4,

- Y is in each case independently a photoactivatable protective group as claimed in claim 1, Z is an amino protective group, and where  $R_1$  or/and  $R_2$  may optionally be replaced by Y.
- 20 6. The process as claimed in any of claims 1 to 5, characterized in that a photoactivatable group of the general formula (II) is used



in which Ar is a fused polycyclic fluorescent aryl or heteroaryl,

 $S_1$  and  $S_2$  are each independently selected from hydrogen, a  $C_1$ - $C_8$ -alkyl group, a  $C_2$ - $C_8$ -alkenyl group, a  $C_2$ - $C_8$ -alkynyl group, a  $C_6$ - $C_{25}$ -aryl group or a  $C_5$ - $C_{25}$ -heteroaryl group, each of which may optionally have substituents, and Q is a group for linking the photolabile component to the component which can be eliminated

to the component which can be eliminated chemically.

5

25

7. The process as claimed in any of claims 1 to 5, characterized in that a photoactivatable group of the general formula (III) is used:

$$T_{5}$$

$$T_{7}$$

$$T_{1}$$

$$T_{2}$$

$$Q_{1}$$

$$Z_{1}$$

$$Z_{2}$$
(IIII)

in which  $T_1$ ,  $T_2$ ,  $T_3$ ,  $T_4$ ,  $T_5$  and  $T_6$  are each independently selected from hydrogen,  $C_1$ - $C_8$ -alkyl,  $C_2$ - $C_8$ -alkenyl,  $C_2$ - $C_8$ -alkynyl,  $C_1$ - $C_8$ -alkoxy,  $C_2$ - $C_8$ -alkoxycarbonyl,  $C_6$ - $C_{20}$ -aryl or aryloxy or/and  $C_5$ - $C_{25}$ -heteroaryl or heteroaryloxy, each of which may optionally have substituents,

and  $T_1$  or/and  $T_2$  may additionally be trialkylsilyl, and one of  $T_3$  and  $T_4$  may be  $NO_2$ , with the proviso that the other is then H,

 $Q_1$  is hydrogen, optionally substituted  $C_1-C_4$ -alkoxy or di( $C_1-C_4$ -alkyl)amino,

30  $Z_1$  and  $Z_2$  together are -OC(0)-,  $-NT_7C(0)-$  or  $-CT_8=CT_9$ , where  $T_8$  and  $T_9$  are defined as  $T_3-T_6$ , and  $T_9$  may additionally be  $NO_2$ , and adjacent groups T may optionally form a 5- or

6-membered carbocyclic or heterocyclic, saturated or unsaturated ring, and Q is a group for linking the photolabile component to the component which can be eliminated chemically.

8. The process as claimed in any of claims 1 to 5, characterized in that a photoactivatable group of the general formula (IV) is used:

10

5

$$U_3$$
 $U_2$ 
 $U_5$ 
 $Q$ 
 $(V)$ 

in which  $U_1$ ,  $U_2$ ,  $U_4$  and  $U_5$  are each independently selected from hydrogen, halogen, NO2, U6, (L)-U6,  $O-(L)-U_6$ ,  $N(U_6)_2$  and NHZ,  $U_6$  is  $C_1-C_8-alkyl$ , 15  $C_2-C_8$ -alkynyl,  $C_6-C_{25}$ -aryl  $C_2-C_8$ -alkenyl, C<sub>5-</sub>C<sub>25</sub>-heteroaryl, each of which may optionally have substituents, L is a linker group which is optionally present, U3 is a label optionally linked via a linker group, and 20 Q is a group for linking the photolabile component be eliminated which can to the component chemically.

25 9. The process as claimed in any of claims 1 to 5, characterized in that a photoactivatable group of the general formula (V) is used:

$$V_4$$
 $V_2$ 
 $V_5$ 
 $V_6$ 
 $V_8$ 
 $V_8$ 
 $V_8$ 
 $V_8$ 
 $V_9$ 
 $V_9$ 

in which  $V_1$ ,  $V_2$ ,  $V_3$ ,  $V_4$ ,  $V_5$  and  $V_6$  are each independently selected from hydrogen, halogen,  $NO_2$ ,  $V_7$ ,  $(L)-V_7$ ,  $O_-(L)-V_7$ ,  $N(V_7)_2$ , NHZ and M, where  $V_7$  is  $C_1-C_8$ -alkyl,  $C_2-C_8$ -alkenyl,  $C_2-C_8$ -alkynyl,  $C_6-C_{25}$ -aryl or  $C_5-C_{25}$ -heteroaryl, each of which may optionally have substituents, L is a linker group which is optionally present and  $V_5$  and  $V_6$  may additionally be trialkylsilyl, M is a label optionally linked via a linker group, and Q is a group for linking the photolabile component to the component which can be eliminated chemically.

- 15 10. The process as claimed in any of claims 1 to 9, characterized in that the two-stage protective group carries a plurality of labeling groups which can be detected independently of one another.
- 20 11. The process as claimed in claim 10, characterized in that a first label is linked to the photolabile component and a second label is linked to the component which can be eliminated chemically.
- 25 12. The process as claimed in any of claims 5 to 11, characterized in that the two-stage protective group comprises at least one fluorescent label.
- 13. The process as claimed in claim 12, characterized in that a fluorescent label is introduced on the trityl framework of a compound (I).
  - 14. The process as claimed in any of claims 1 to 13, characterized in that the biopolymers are selected

from nucleic acids, nucleic acid analogs, peptides and saccharides.

- 15. The process as claimed in claim 14, characterized in that the biopolymers are selected from nucleic acids and nucleic acid analogs.
- 16. The process as claimed in claim 15, characterized in that phosphoramidites are used as synthesisbuilding blocks.
  - 17. The process as claimed in claim 16, characterized in that phosphoramidite building blocks carrying the two-stage protective group on the 5'-0 atom are used.

15

20

25

30

35

- 18. The process as claimed in any of claims 1 to 17, characterized in that the synthesis of the biopolymers includes the use of spacer and/or linker building blocks.
- 19. The process as claimed in any of claims 1 to 18, characterized in that the synthesis of the biopolymers is carried out on a solid phase.
- 20. The process as claimed in claim 19, characterized in that a location-dependent synthesis of a plurality of biopolymers is carried out with in each case a different sequence of synthesis building blocks on a single support.
  - 21. The process as claimed in any of claims 1 to 20, characterized in that a synthesis building block with two-stage protective group is used for quality control.
  - 22. Compounds of the general formula (I)

$$R_2$$
 $M_{in}$ 
 $M_{in}$ 
 $M_{in}$ 
 $M_{in}$ 
 $M_{in}$ 
 $M_{in}$ 

where  $R_1$ , Y, M and m are defined as in claim 1, and X is a synthesis building block or a leaving group, where  $R_1$  or/and  $R_2$  may optionally be replaced by Y.

5

15

20

- 23. Compounds as claimed in claim 22, characterized in that they carry a plurality of labels detectable independently of one another.
  - 24. Compounds as claimed in claim 22 or 23, characterized in that they carry at least one fluorescent label.
- 25. The use of compounds of the general formula (I) as synthesis building blocks or for preparing synthesis building blocks for the synthesis of biopolymers.
  - 26. The use as claimed in claim 25 for quality control during the synthesis of biopolymers on a solid support.